Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Appointment InformationThe strategy for and management of IDSO is steered by David Jaffray, Ph.D., Caroline Chung, M.D., and co-leads of the institute's five focus areas. With a strong focus on servant leadership, these leaders’ responsibility is to build data science capabilities across the organization — fostering ideas, securing philanthropic support and planning for operational needs to enable this growing community.
IDSO is committed to collaborating with and leveraging the expertise of our faculty, data scientists, data abstracters and researchers. To build upon our multi-disciplinary approach to cancer patient care and research, MD Anderson seeks to attract, engage with and build the best minds and collaborations in data science through IDSO.
David Jaffray, Ph.D.
Chief Technology and Digital Officer and Senior Vice President
Professor, Radiation Physics and Imaging Physics
Director of IDSO
Dr. Jaffray is world-renowned for pioneering state-of-the-art image-guided radiation therapy, advancing the science and practice in medical physics, and for international leadership in clinical data science for oncology. Recruited to MD Anderson in May 2019, Dr. Jaffray serves as the IDSO director and is the institution’s inaugural chief technology and digital officer, bringing more than two decades of scientific expertise and proven skill as an innovator. In this role, he directs the strategic design, acquisition, management and implementation of an enterprise-wide technology infrastructure to safeguard the integrity and availability of the institution’s systems and intellectual property assets. He and his leadership team advance data integration, data governance and data security across MD Anderson’s campuses and its national network, as well as coordinate technology-enabled innovation. He also is a professor with dual appointments for Radiation Physics and Imaging Physics.
Over the course of his career, he has played an important role in bridging the fields of biomedical engineering and medical physics. He continues to facilitate dialog and partnership between these two important disciplines and how they can tackle major health challenges worldwide. For his leadership, Dr. Jaffray was recognized in 2021 as a Fellow of the International Union for Physical and Engineering Sciences in Medicine and in 2022 as a Fellow of the National Academy of Inventors.
Dr. Jaffray holds 47 patents and has authored more than 300 peer-reviewed publications in cancer science and technology, including the development of new radiation treatment machines, the exploration of the fundamental limits of imaging system performance, the development of novel nanoparticle formulations for improved detection of cancer, and challenges in global health.
Caroline Chung, M.D.
Chief Data Officer and Vice President for Data Impact and Governance
Associate Professor, Radiation Oncology and Diagnostic Radiology
Director of Data Science Development and Implementation, IDSO
As the institution’s first-ever chief data officer, Dr. Chung is responsible for shaping MD Anderson’s data strategy and leading its implementation from an operational and cultural perspective. She oversees the Data Impact and Governance department and institutional data offices, as well as leads the formation of the principles, policies and programs for stewardship, advocacy and custodianship of data.
Dr. Chung holds several leadership positions to facilitate quantitative measurement and clinically impactful interpretation of data, as well as team science and collaborative imaging efforts. She serves as co-chair of the Tumor Measurement Initiative at MD Anderson, which aims to build an institutional platform for standardized, automated quantitative imaging-based tumor measurement across each patient’s journey to advance multidisciplinary, data-driven and high-precision cancer treatment.
Amidst the COVID-19 pandemic, Dr. Chung has been integrally involved in the establishment of the Data-Driven Determinants of COVID-19 in Oncology Discovery Effort (D3CODE) that fosters a team data science approach to aggregate and analyze data across internal and external collaborative teams. To further enable the D3CODE effort, she has been leading the development of the supporting infrastructure and data governance processes, including data provenance, quality and ontology, which has been formalized into the Data Governance Program, which she co-chairs.
Dr. Chung’s clinical practice includes the treatment of primary and secondary CNS neoplasms. Her primary research interests focus on the discovery of clinically impactful quantitative imaging biomarkers through the development of novel tools to help standard image acquisition (including the development of novel immobilization devices and imaging approaches), image processing and analysis, including the development of AI-based models.
Bissan Al-Lazikani, Ph.D.
Co-lead, Computational Modeling for Precision Medicine
Professor, Genomic Medicine
Dr. Al-Lazikani is a data scientist and drug discoverer formally trained in molecular biology and computer science with experience in academia and industry. She serves as the director of Therapeutics Data Science and co-lead for IDSO’s Computational Modeling for Discovery, Development and Optimization of Precision Medicine focus. Prior to being recruited to MD Anderson in 2021, she was the head of Data Science at the Institute of Cancer Research, London.
Her research focus is developing AI approaches and tools to address key bottlenecks in drug discovery and development, and to discover novel therapeutics for cancer. These approaches rely on the smart integration of vast, multidisciplinary research and clinical data. She sees AI as a natural part of health care that supports and augments clinicians’ decisions and address a challenge of cancer research to drive objective, data-informed decisions across drug discovery and development, and accelerate innovative drugs to our patients.
Dr. Al-Lazikani co-led the creation of the groundbreaking ChEMBL database. Then she led the creation of the world’s largest public drug discovery knowledgebase, canSAR.ai, – integrating a vast amount of multidisciplinary data and AI-driven drug discovery analysis algorithms. CanSAR.ai, used by hundreds of thousands of researchers across the world, is now hosted at MD Anderson as part of our commitment to enable and democratize cancer drug discovery.
Dr. Al-Lazikani was named one of 15 Fellows of the International Society for Computational Biology (ISCB) for 2023. The ISCB Fellows program was created to honor members who have distinguished themselves through outstanding contributions to the fields of computational biology and bioinformatics. She is a 2012 recipient of the AACR Team Science Award and in 2021 she became a CPRIT Scholar of Cancer Research, as well as a Fellow of the Royal Society of Biology. She is a chartered member of the British Computing Society. In 2018, she was elected to the University of London’s Leading Women, which celebrates exceptional women by sharing stories of women leading both, by being the first, and by leading through their inspirational educational and professional achievements. She is passionate about mentoring and supporting women and underrepresented groups in science.
Heiko Enderling, Ph.D.
Co-lead, Computational Modeling for Precision Medicine
Professor, Radiation Oncology
Dr. Enderling, an internationally renowned mathematical oncologist, joined MD Anderson in 2023. His appointment as professor in Radiation Oncology reflects his more than 2 decades of interdisciplinary experience and leadership in computational modeling of tumor growth and radiation response dynamics. In addition, he serves as the Director of the Computational Modeling in Radiation Oncology Program and co-lead for IDSO’s focus on Computational Modeling for Precision Medicine. He translated the first-of-its-kind mathematical model biomarker into successful prospective clinical translation to improve responses and outcomes for head and neck cancer radiotherapy patients. Dr. Enderling has developed rigorous standards for mathematical and computational models in oncology in general, and radiation oncology, with special emphasis on data-driven model calibration, validation, and clinical translation.
He joined Moffitt Cancer Center in 2013 in the Integrated Mathematical Oncology department where he led the Quantitative Personalized Oncology lab and served as Director for Education and Outreach. He founded and directed multiple research and education programs that propelled the careers of many students and postdoctoral fellows.
Dr. Enderling has authored over 100 publications in applied mathematics, computer science, cancer research, radiobiology and radiation oncology. He developed and championed integrated model development platforms and predictive modeling pipelines for clinical translation. He is a Fellow of the Society for Mathematical Biology, which he also served on the Board of Directors for 8 years, and more recently as Vice President and President.
Jeffrey Siewerdsen, Ph.D.
Co-lead, Safety, Quality and Access
Professor, Imaging Physics – Research
Dr. Siewerdsen, an internationally recognized physicist and biomedical engineer, joined MD Anderson in 2022. His multi-disciplinary expertise is reflected in his appointment as professor in Imaging Physics with joint appointments in Neurosurgery and Radiation Physics. In addition, he serves as the director of the Surgical Data Sciences Program and co-lead for IDSO’s Development of Automated Approaches to Increase Access, Safety and Quality focus. Dr. Siewerdsen’s primary appointment is in Imaging Physics, and his research in surgical data science aims to develop and implement novel technologies and computational models in surgery. He also serves as a liaison and strategist for operations, research and education in Surgery.
Over the last two decades, Dr. Siewerdsen led the development of cone-beam CT systems for numerous applications in diagnostic and image-guided procedures. He joined Johns Hopkins in 2009, where he served as John C. Malone Professor and vice-chair in Biomedical Engineering as well as co-director of The Carnegie Center for Surgical Innovation. He founded the I-STAR Lab (Imaging for Surgery, Therapy and Radiology) as a collaboration among engineering and clinical experts, serving as a launching-pad for numerous investigators now leading independent research programs. Technologies bearing his thumbprint include cone-beam CT for surgery, interventional and diagnostic radiology, and radiation therapy as well as novel algorithms for 3D image reconstruction and multi-modality, deformable image registration.
Dr. Siewerdsen has authored more than 200 publications and is a serial inventor with over 60 granted patents in the domains of imaging, radiation oncology and surgery. He helped to coin the term “surgineering” as a new approach to education and deep collaboration among engineers and surgeons in systems engineering and data science to improve surgical safety, quality and workflow.
Eric Stahlberg, Ph.D.
Executive Administrative Director, IDSO
Dr. Stahlberg has a significant and sustained track record of working at the intersection of biology and data-intensive computing to deliver impactful outcomes to diverse stakeholders. Over the course of his career, he has led multiple transformative initiatives, including advancing medical digital twins, helping transform fragmented laboratory data to emerge as an enterprise asset and initiating large cross-organization collaborations in computing and AI solutions. In pursuit of these efforts, he has developed cutting-edge bioinformatics software as well as innovative solutions for data management, AI model management, and information delivery.
Dr. Stahlberg joins MD Anderson from the Frederick National laboratory for Cancer Research where he directed all cancer data science initiatives. While there, he helped establish their HPC initiative and played a leadership role in many key partnerships, including forming the collaboration between the National Cancer Institute and the Department of Energy where the agencies are accelerating progress in precision oncology and computing. Other major initiatives he has been instrumental in executing include IMPROVE (Innovative Methods and New Data for Predictive Oncology Model Evaluation), the Predictive Oncology Model and Data Clearinghouse (modac.cancer.gov), and ATOM (Accelerating Therapeutics for Opportunities in Medicine). He has further led program efforts establishing foundations for digital twin applications in cancer and advancing personalized medicine for all individuals through virtual human models and digital twin approaches.
Dr. Stahlberg’s proven leadership and commitment to education, outreach, and collaboration will further help propel the IDSO — advancing data science-based solutions to improve decision-making, accelerate and transform research, and bring impact to MD Anderson and the patients we serve.
Dr. Wang is a pioneering computational biologist and data scientist with formal training in clinical medicine, cancer genomics, and bioinformatics. She is a tenured associate professor of Genomic Medicine and an associate member of the James P. Allison Institute at MD Anderson. As co-lead for Focus Area 2 at IDSO, “Single Cell Spatial Omics to Unveil Cancer Complexity,” Dr. Wang is dedicated to building a world-class data science hub for single-cell and spatial multi-omics studies to accelerate discovery and translation in cancer research and drive breakthroughs at MD Anderson and beyond.
Dr. Wang’s research focuses on unraveling the complexity and evolution of tumor ecosystems in space and time at unprecedented resolution, encompassing cellular and molecular heterogeneity, phenotypic plasticity, dynamics and interactions within the tumor microenvironment during cancer initiation, progression, response and resistance to therapy. Her team leverages cutting-edge single-cell and spatial multi-omics technologies, high-plex cellular and molecular imaging and advanced machine learning and computational modeling to address fundamental questions and drive breakthroughs in cancer research. Since joining MD Anderson, Dr. Wang has established a leading research program in computational biology and built a truly collaborative, team-based approach to drive innovation in basic and translational cancer research. Her group consistently delivers highly innovative and influential works, and their groundbreaking research has significantly advanced the field.
Dr. Wang has an outstanding record of research productivity, having authored more than 130 publications, with more than 50 of these as a first or senior author in high-impact journals. She serves as the Lead PI of an NIH/NCI R01, an NCI/HTAN PreCancer U01 Center, and as a MPI of an NCI/CSBC U01, as well as an Individual Investigator Research Awards funded by CPRIT. She also co-leads the Data Science Hub funded by Break Through Cancer, serves as lead of the Data Analysis and Visualization Unit for an NCI/PSRC U24 and is the program co-leader of the Moon Shot Multiple Myeloma Program. Her infectious enthusiasm and passion for rigorous cancer research and sustained academic excellence have made her an internationally recognized investigator in the field. She has been invited to serve on numerous grant review panels for the NIH/NCI and other national research societies and foundations within and outside of the United States and has served as a session chair or invited speaker for prestigious scientific conferences such as the Annual Meetings of AACR and SITC.
Dr. Wang has been honored with the Emil Frei, III Award for Excellence in Translational Research; the David M. Livingston Collaboration Award; and the Sabin Fellow Award. Her collaborative approach, both within MD Anderson and with national and international partners, has positioned her at the forefront of cancer research, contributing to transformative discoveries that have advanced our understanding and treatment of cancer. As co-lead of Focus Area 2 at IDSO, she works closely with other experts and researchers, continuing to push the boundaries to uncover novel biomarkers and therapeutic targets in cancer, harnessing the power of data science to better understand, detect and treat cancer.
Yinyin Yuan, Ph.D.
Co-lead, Quantitative Pathology and Medical Imaging
Professor, Translational Molecular Pathology
Dr. Yuan is widely acknowledged as one of the leading experts in computational pathology. Her scientific focus is to decipher the tumor ecosystem that shapes the emergence of immune evasion and drug resistance. She has a strong track record in developing cutting-edge machine learning and data science approaches to study the dynamic crosstalk among genetically diverse cancer cells and their microenvironment.
As the co-lead for IDSO’s Quantitative Analysis and Insight Extraction from Pathology and Medical Imaging focus – Dr. Yuan is committed to building the computational infrastructure and data science capacity for pathology. She is designing impact-driven strategies to enable accelerated, rigorous, and actionable approaches for building data science capacity with translational impacts in pathology. The vision is to create a new paradigm of technological advances and multidisciplinary convergences that will lead the way to novel digital biomarkers and ultimately to the new frontier of integrated diagnostics.
Before joining MD Anderson in Oct 2022, she founded the Computational Pathology and Integrative Genomics laboratory at the institute of Cancer Research, London, in 2012. She successfully built a pioneering interface between digital pathology, data science, and cancer biology with strong clinical applications, and was awarded the title of Professor of Computational Pathology in 2021. Her team leads computational pathology in many international scientific programs and consortiums, including the Cancer Research UK program TRACERx, Sarcoma Network Accelerator, Early Detection for Smoldering Myeloma, Brain Tumour award Target-GBM, H2020 CONTRA, and the NIH Arizona Cancer Evolution Center and Breast Pre-Cancer Atlas.
Affiliates bring diverse expertise to facilitate engagement, advance the work of the institute and grow the data science ecosystem at MD Anderson.
